Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall... by Diéras, Véronique, Dr, Miles, David, Prof, Verma, Sunil, MD, Pegram, Mark, Prof, Welslau, Manfred, MD, Baselga, José, MD, Krop, Ian E, MD, Blackwell, Kim, Prof, Hoersch, Silke, MSc, Xu, Jin, PhD, Green, Marjorie, MD, Gianni, Luca, MD

Get full text

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results fr... by Krop, Ian E, Dr, Kim, Sung-Bae, Prof, Martin, Antonio Gonzalez, MD, LoRusso, Patricia M, Prof, Ferrero, Jean-Marc, MD, Badovinac-Crnjevic, Tanja, MD, Hoersch, Silke, MSc, Smitt, Melanie, MD, Wildiers, Hans, Prof

Get full text

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 tri... by Krop, Ian E, Dr, Mayer, Ingrid A, MD, Ganju, Vinod, FRACP, Dickler, Maura, MD, Johnston, Stephen, MD, Morales, Serafin, MD, Yardley, Denise A, MD, Melichar, Bohuslav, Prof, Forero-Torres, Andres, MD, Lee, Soo Chin, MRCP, de Boer, Richard, FRACP, Petrakova, Katarina, PhD, Vallentin, Susanne, MD, Perez, Edith A, MD, Piccart, Martine, Prof, Ellis, Matthew, Prof, Winer, Eric, Prof, Gendreau, Steven, PhD, Derynck, Mika, MD, Lackner, Mark, PhD, Levy, Gallia, MD, Qiu, Jiaheng, PhD, He, Jing, MD, Schmid, Peter, Prof

Get full text

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial by Krop, Ian E, Dr, Kim, Sung-Bae, Prof, González-Martín, Antonio, MD, LoRusso, Patricia M, Prof, Ferrero, Jean-Marc, Prof, Smitt, Melanie, MD, Yu, Ron, PhD, Leung, Abraham C F, MD, Wildiers, Hans, Prof

Get full text